Drug efficacy

Animal models for Parkinson Disease?

We just came back from the last edition of “World Congress on Parkinson’s Disease and Related Disorders” that took place last week on Geneva, Switzerland. This International congress brought together leading clinical and pre-clinical experts, scientists from University and Pharmaceutical Companies to elaborate new strategies and make a point on the most recent research and updates on pathogenesis, last biomarkers and treatment modalities of Parkinson’s disease. It was a good opportunity for S...

New PAH results with the Monocrotaline model

Pulmonary Arterial Hypertension (PAH) is an orphan disease, incurable that remains highly lethal despite recent advanced medical treatment. Various pharmacological therapies such as Prostacyclines, Endothelin receptor antagonists, PDE5 inhibitors have been reported for PAH diseases. In spite of these treatments, the average of survival is 2,8 years so new treatments must be developed. This growing recognition of these health problems, and their risks, increases our need for effective resea...
Waygo : Agence webmarketing